Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2017 | 130 | 1.320 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2017 | 13 | 1.250 |
Why?
|
| Thyroidectomy | 3 | 2020 | 18 | 1.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2017 | 7 | 1.150 |
Why?
|
| Hypocalcemia | 2 | 2020 | 13 | 1.110 |
Why?
|
| Parathyroidectomy | 2 | 2020 | 15 | 0.830 |
Why?
|
| Calcium | 3 | 2020 | 304 | 0.810 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 8 | 0.700 |
Why?
|
| Temporal Bone | 1 | 2019 | 21 | 0.690 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 18 | 0.680 |
Why?
|
| Postoperative Complications | 3 | 2020 | 779 | 0.640 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 9 | 0.560 |
Why?
|
| Chemokines | 1 | 2016 | 36 | 0.550 |
Why?
|
| Esophageal Stenosis | 3 | 2011 | 6 | 0.540 |
Why?
|
| Thyroid Neoplasms | 2 | 2008 | 31 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 154 | 0.510 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 41 | 0.510 |
Why?
|
| MicroRNAs | 1 | 2017 | 180 | 0.490 |
Why?
|
| Hypercalcemia | 1 | 2014 | 9 | 0.470 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 7 | 0.470 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2014 | 9 | 0.460 |
Why?
|
| Adenoma | 1 | 2014 | 35 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2006 | 461 | 0.430 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 409 | 0.410 |
Why?
|
| Early Diagnosis | 1 | 2011 | 62 | 0.390 |
Why?
|
| Plicamycin | 1 | 2011 | 1 | 0.390 |
Why?
|
| Burns, Chemical | 1 | 2011 | 7 | 0.390 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 13 | 0.390 |
Why?
|
| Female | 22 | 2020 | 19859 | 0.360 |
Why?
|
| Middle Aged | 18 | 2020 | 11824 | 0.360 |
Why?
|
| Collagen | 1 | 2011 | 225 | 0.350 |
Why?
|
| Aged | 16 | 2020 | 10288 | 0.340 |
Why?
|
| Treatment Outcome | 10 | 2019 | 3294 | 0.340 |
Why?
|
| Male | 19 | 2020 | 19091 | 0.340 |
Why?
|
| Humans | 28 | 2020 | 31836 | 0.340 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2008 | 1 | 0.310 |
Why?
|
| Eosinophilia | 1 | 2008 | 12 | 0.310 |
Why?
|
| Smoking | 3 | 2016 | 499 | 0.290 |
Why?
|
| Salivary Glands | 3 | 2017 | 14 | 0.280 |
Why?
|
| Adult | 13 | 2020 | 9327 | 0.260 |
Why?
|
| Submandibular Gland | 1 | 2005 | 4 | 0.260 |
Why?
|
| Hypopharynx | 1 | 2004 | 2 | 0.250 |
Why?
|
| Gastroscopy | 1 | 2004 | 8 | 0.250 |
Why?
|
| Laryngoscopy | 1 | 2004 | 40 | 0.240 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 725 | 0.240 |
Why?
|
| Retrospective Studies | 7 | 2020 | 3488 | 0.240 |
Why?
|
| Ventilator Weaning | 1 | 2004 | 3 | 0.240 |
Why?
|
| Length of Stay | 3 | 2019 | 315 | 0.240 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 32 | 0.230 |
Why?
|
| Carcinoma | 1 | 2005 | 92 | 0.230 |
Why?
|
| Clinical Protocols | 1 | 2004 | 99 | 0.230 |
Why?
|
| Cross Infection | 1 | 2004 | 49 | 0.230 |
Why?
|
| Neck Dissection | 4 | 2008 | 9 | 0.230 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 98 | 0.220 |
Why?
|
| Time Factors | 3 | 2019 | 2146 | 0.220 |
Why?
|
| Combined Modality Therapy | 8 | 2014 | 564 | 0.210 |
Why?
|
| Taxoids | 5 | 2006 | 59 | 0.210 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 531 | 0.190 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 48 | 0.170 |
Why?
|
| Paclitaxel | 3 | 2005 | 67 | 0.170 |
Why?
|
| Vitamin D | 1 | 2020 | 183 | 0.160 |
Why?
|
| Prognosis | 3 | 2020 | 1498 | 0.150 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2017 | 9 | 0.150 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2017 | 9 | 0.150 |
Why?
|
| Micronutrients | 1 | 2017 | 18 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 120 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2017 | 61 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 3988 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 334 | 0.130 |
Why?
|
| Cesium Radioisotopes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Laryngeal Muscles | 1 | 2015 | 16 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 25 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 194 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 35 | 0.130 |
Why?
|
| Muscle Proteins | 1 | 2015 | 59 | 0.130 |
Why?
|
| Self Disclosure | 1 | 2015 | 22 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 221 | 0.130 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 70 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2006 | 77 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 261 | 0.120 |
Why?
|
| Mucositis | 1 | 2014 | 8 | 0.120 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 10 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2014 | 18 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2014 | 20 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 95 | 0.110 |
Why?
|
| Salivary Glands, Minor | 1 | 2013 | 10 | 0.110 |
Why?
|
| Reference Values | 2 | 2011 | 247 | 0.110 |
Why?
|
| Thyroid Diseases | 1 | 2011 | 6 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2011 | 2271 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2011 | 20 | 0.100 |
Why?
|
| ROC Curve | 1 | 2011 | 167 | 0.100 |
Why?
|
| Carboplatin | 3 | 2006 | 48 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2006 | 192 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2011 | 140 | 0.090 |
Why?
|
| Random Allocation | 1 | 2011 | 218 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 518 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 899 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 311 | 0.090 |
Why?
|
| Dilatation | 1 | 2010 | 8 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 456 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 874 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 738 | 0.080 |
Why?
|
| Sclerosis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2014 | 1431 | 0.080 |
Why?
|
| Cisplatin | 5 | 2006 | 77 | 0.080 |
Why?
|
| Fluorouracil | 5 | 2006 | 82 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 1012 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 40 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 1586 | 0.070 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 1 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2006 | 9 | 0.070 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 50 | 0.070 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 15 | 0.060 |
Why?
|
| Xerostomia | 1 | 2005 | 30 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 49 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 7450 | 0.060 |
Why?
|
| Fibrosis | 1 | 2005 | 118 | 0.060 |
Why?
|
| Pharyngeal Diseases | 1 | 2004 | 9 | 0.060 |
Why?
|
| Nasal Bone | 1 | 2004 | 5 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 45 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 42 | 0.060 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 1 | 0.060 |
Why?
|
| Respiratory Therapy | 1 | 2004 | 4 | 0.060 |
Why?
|
| Incidence | 2 | 2006 | 1192 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1527 | 0.060 |
Why?
|
| Infection Control | 1 | 2004 | 28 | 0.060 |
Why?
|
| Fetus | 1 | 2004 | 86 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2004 | 111 | 0.060 |
Why?
|
| Age Distribution | 1 | 2004 | 206 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2004 | 109 | 0.060 |
Why?
|
| Critical Care | 1 | 2004 | 107 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2004 | 190 | 0.050 |
Why?
|
| Tissue Engineering | 2 | 2007 | 655 | 0.050 |
Why?
|
| Risk Factors | 2 | 2015 | 3851 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 540 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2015 | 292 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2015 | 2277 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 884 | 0.040 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 30 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 26 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2017 | 38 | 0.040 |
Why?
|
| Demography | 1 | 2016 | 110 | 0.030 |
Why?
|
| Antioxidants | 1 | 2017 | 114 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 52 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2015 | 20 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 523 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 170 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2017 | 185 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2476 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2014 | 82 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 833 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 319 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 766 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 764 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 224 | 0.030 |
Why?
|
| Eating | 1 | 2010 | 74 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 607 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 912 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2007 | 12 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 32 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 84 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 101 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 37 | 0.020 |
Why?
|
| Laryngectomy | 1 | 2005 | 3 | 0.020 |
Why?
|
| Aquaporin 5 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2005 | 4 | 0.020 |
Why?
|
| Aquaporins | 1 | 2005 | 5 | 0.020 |
Why?
|
| alpha-Amylases | 1 | 2005 | 4 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 47 | 0.020 |
Why?
|
| Keratins | 1 | 2005 | 39 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2004 | 10 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2004 | 9 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2004 | 23 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2005 | 134 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 468 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 259 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 120 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 291 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 593 | 0.010 |
Why?
|
| Organoids | 1 | 2005 | 94 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 385 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 257 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 25 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 24 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 11 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 14 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 635 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 162 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 369 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 272 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 1824 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 487 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 994 | 0.010 |
Why?
|
| Quality of Life | 1 | 2006 | 924 | 0.010 |
Why?
|